Open in interactive viewer → charts, metric popovers & call review

MiNK's First Revenue Is Real—and Still Too Small to Matter

A named-patient program, an ARPA-H stamp and a bigger ARDS trial change the story; the cash runway and a 2027 readout still set the terms.
INKT · Earnings Call · 2026-11-11
MiNK Therapeutics reported a quarter that looks, on the surface, like a milestone: “physician demand has produced patient access outside of clinical trials and marks our first revenue with agenT-797” — Jennifer Buell · 2026-11-11. The tape disagrees. At a $52 million market cap, the stock is still down 91.5% from its 2021 peak; the recent 90-day tape is roughly flat, and shares sit about 20% below the October 1 high after a 222% nine-day run earlier in the year. The market is treating the first revenue as a curiosity, not a validation. That is the right read: the revenue is real but tiny, variable and granted case-by-case; the binary is still the randomized ARDS readout in 2027.

From Brazil to a P&L line

On the prior call, Mayank Mamtani asked about the Brazil paid program. CEO Jennifer Buell confirmed it was active and said, “we have patients in and we will be reporting that those patients were brought in just after the close of the quarter. So we'll be announcing some of the financials in our Q3 update” — Jennifer Buell, Chief Executive Officer · 2026-08-13. She kept that promise. This quarter, MiNK recognized its first pre-commercial product revenue from agenT-797 supplied through its named patient access program. That is a genuine change: the company now has a commercial funnel, however narrow, outside a clinical trial. But the call never puts a dollar figure on the revenue. Management says demand will “vary from quarter-to-quarter based on physician requests and case-by-case regulatory authorizations” — Melissa Orilall · 2026-11-11. Investors should treat it as proof of logistics and physician pull, not as a revenue base. The first paid patient is a milestone; the first repeatable paid cohort is a business.

The trial got bigger, and the endpoint got earlier

Here is the more important change. In May, Buell described the randomized Phase II as “90 patients split at 1:1 randomization” — Jennifer Buell, Chief Executive Officer · 2026-05-15. On the August call, when asked about a 90-patient target, she said “We haven't spoken to specific numbers of patients enrolled at this time” — Jennifer Buell, Chief Executive Officer · 2026-08-13. Yesterday, the design was formalized at a larger size and a different endpoint:

The initial randomized stage will enroll about 124 patients with the ability to expand to as many as 300 patients. The proposed endpoint is hierarchical, survival without VV-ECMO at day 14, followed by all-cause mortality through day 28.

Jennifer Buell · 2026-11-11
That is not cosmetic. The prior framing emphasized 28-day mortality as the FDA-driven primary. The new design uses VV-ECMO-free survival at day 14 first, then mortality. It is a win-ratio-style hierarchy that may capture the bedside decision that matters most—keeping ARDS patients off the most invasive life support—and could make a smaller trial more efficient. It also adds complexity and FDA dependence. Management plans to meet the agency before year-end to see whether the randomized stage can feed directly into a registration-enabling Phase III. If the FDA agrees, the 2027 readout becomes an inflection point. If not, the timeline reverts to a conventional Phase II/III gap. The endpoint also depends on Lviv and U.S. sites being comparable. Dr. Terese Hammond spends time defending that: “We also visited Lviv Ukraine prior to deciding on enrolling that site to really validate in person that the same standards we use in the United States when patients are admitted with ARDS are adhered to in the Lviv ICUs” — Terese Hammond · 2026-11-11. U.S. activation is aimed at high-volume medical and surgical ICUs that can escalate to ECMO. That is a shift in emphasis from the prior quarter's long discussion of conflict zones and pan-resistant organisms spreading into Europe. The war-zone story was vivid; the U.S. ICU story is what regulators will actually review.

Cash, calendar and the things that slipped

Melissa Orilall's financial update is candid: “We ended the quarter with $7.5 million in cash and cash equivalents compared to $8.8 million at June 30” — Melissa Orilall · 2026-11-11. Cash used in operations was $1.3 million, the lowest quarter of the year, and net loss was $2.6 million. The company also says it “will strengthen our balance sheet with additional funding and currently meet the requirements as a going concern” — Melissa Orilall · 2026-11-11. That is not a comfortable phrase from a $52 million biotech with a randomized trial to fund. The last filed quarter shows the cost base moving in two directions: G&A was cut 44%, while research and development rose to about $2 million, up 57% sequentially. Cash runway, at 4.2 quarters, is better than the 2025 trough but still leaves little margin for the 2027 readout. Nondilutive money helps: the ARPA-H BoSS program commits up to $87 million over four years, and the GvHD study is externally funded through NIAID and the Mary Gooze award. But ARPA-H pays on a fixed-fee basis as MiNK performs; it is reimbursement for work, not a blank check. The global keyword list had ARPA-H in the top 75 for the quarter, so the government biostabilization theme is real—but there is no price tape voting on it, and it does not solve the near-term financing gap. The GvHD program is a reminder that the calendar is not fully under management's control. Buell says first dosing at Wisconsin is expected by December, but concedes “The start, while it has moved from our first half guidance, is now moved to the second half” — Jennifer Buell · 2026-11-11. That is a second-half slip, not a new program. Investors should apply the same skepticism to the U.S. ARDS site activation 'before year-end' language.

What would make the first revenue matter

The bull case is not the named-patient line. It is that agenT-797 is a single off-the-shelf product that can be deployed across critical care, idiopathic pulmonary fibrosis and oncology—and that the same biology reads the disease environment. Dr. Hammond's description of patients in Lviv—fevers resolving, oxygenation improving, immune markers tracking recovery—is exactly the kind of pattern that makes a randomized trial worth running. The senolytic and senescent cell data add a mechanistic bridge from acute inflammation to chronic fibrosis. But those are still early signals. The current quarter's real news is narrower: MiNK has a paid access program, a larger randomized trial and an FDA meeting that could shorten the path. The stock has already shown it will trade the story violently; the fundamentals have not yet caught up. Until the company discloses revenue dollars and the FDA accepts the adaptive design, the first revenue is a narrative unlock, not a valuation floor.